Key Takeaways
- FY24 delivered, FY25 resets: Revenue grew 30.8% and EBITDA margins hit 30%, but management explicitly guided for a year of normalized, modest growth as the company enters an investment phase.
- The pipeline lag is structural, not a warning: FY23-24 growth came from projects added in FY19-20; the current pickup in RFPs and new project inflows will add meaningfully only 2-3 years out, making FY26-27 the next growth acceleration window.
- Biosecure Act is real but not yet revenue: The narrative has triggered a surge in RFIs and RFPs from American companies, but management was clear that this has not yet converted into a surge in actual business.
- GLP-1 is a generic story, not a CDMO one: The CDMO opportunity is very limited because innovators are building API supply in-house, but the generic opportunity is huge given these are difficult-to-make peptides with global demand.
- What to watch next quarter: Whether the Biosecure Act pipeline converts from conversations into contracts, the pace of new project additions from recovering biotech funding, and any margin normalization beyond the guided investment phase.
FY24 Performance & the Normalization Ahead
- Revenue engine: Total income grew 30.8% in FY24, driven by high growth in the CMS business and steady growth in specialty GDS, both in line with plans.
- Margin journey complete: EBITDA margins climbed from 15% in FY22 to 23% in FY23 to 30% in FY24, consistent with the long-term strategy of building a pure-play API service provider with broad complex capabilities.
- CMS at scale: The CMS business contributed close to 50% of revenues in FY24, with robust growth as some projects near launch while key commercial products continue to scale.
- Prime GDS volatility: Prime products declined 16% YoY due to market share volatility from new nitrosamine regulations and other guidelines; customers' handling choices caused short to medium-term corrections, but no significant long-term impact is seen.
- Q4 in context: Q4 was lower than some previous quarters but in line with expectations and plans for FY24, with significant revenue from both commercial and development projects.
- FY25 reset: Management expects moderation in revenue growth in the short run and normalization to some extent on margins due to investments and input cost increases, while business mix is expected to remain steady and gradually improve.
- Planning discipline: Teams have become more scientific and on top of the planning process; the growing size of the business and better customer visibility help the company end the year more or less as planned.
Sucheth Davuluri: "I think everything we are making in terms of commentary about FY25 and the year beyond, is we are being very realistic. We don't necessarily intend to downplay anything."
The Pipeline Lag & Multi-Year Outlook
- The lag mechanism: Growth achieved in FY23 and FY24 was a result of new projects added in FY19 and FY20; there is always a lag between the performance of a given year and the effort of getting new business.
- FY26-27 acceleration: Management expects growth in FY26 and FY27 to be far better than FY25, based on the current pipeline of products and their projections as they are layered out.
- 3-year visibility: The outlook is based on molecules already in the bank, not on assumptions of new Phase III molecules getting commercialized; anything at that level could enhance the business but is unlikely in the next 1 year and could happen beyond that.
- Medium-term target: Over a 4-5 year period, the company targets 20% kind of growth, though growth will not be linear year-on-year.
- New project inflow recovery: Biotech funding crunch caused a slowdown in new project inflows about a year ago, but the company is now seeing a steady increase in new opportunities and RFPs; in the next 12 months, there should be an increase in the total number of projects.
- Recovery won't help FY25: Any surge in new projects from biotech funding recovery will add more significantly 2-3 years down the line, not necessarily for FY25, per management's response to an analyst question about near-term impact.
Saharsh Davuluri: "If you see the growth that we have achieved in FY23 and FY24 was actually as a result of the new projects we added in FY19 and FY20. So therefore, we would appreciate that there's always going to be a lag between the performance of the year versus the effort of getting a new business."
Biosecure Act & Geopolitical Tailwinds
- Narrative is favorable: American companies are talking to Neuland and other CDMOs about opportunity and projects; conversations would have been fewer without the Biosecure Act discussion.
- RFI/RFP surge, not business surge: There has been a surge in RFI and RFP activity, but management was explicit that this has not yet converted into a surge in actual business.
- China plus one / Europe plus one: The company is seeing customers look at India as an alternative to China, and also seeing customers who would rather keep API manufacturing in Europe.
- European competitors are the real threat: Management noted that most competitors outside India are actually in Europe, and that the company sees less competition from China; European CDMOs and API makers are always a credible threat.
- Differentiation that matters: Neuland's 25-30 year track record with the FDA, strong quality culture, and participation in many INDs, clinical trial manufacturing, NDAs, and PAI inspections set it apart; infrastructure limitations from 4-5 years ago have been addressed.
- Board-level decisions, not procurement-level: The decision of working in India versus keeping a molecule in the West is more of a board decision of the innovator company, and has less to do with whether outsourcing managers or CMC groups have faith in Neuland.
- Taking things as they come: The Biosecure Act bill has not been passed yet; management is focusing on what they control: being in touch with existing and potential customers and matching capabilities to their needs.
Saharsh Davuluri: "We actually see less competition for us in China. And in that sense, the European CDMOs, European API makers are always a credible threat."
GLP-1 & New Molecule Opportunities
- GLP-1 CDMO opportunity is limited: Innovators are securing their own API supply chains by building in-house, so the CDMO side of the opportunity is very constrained.
- GLP-1 generic opportunity is huge: The company does not necessarily have to focus on regulated markets; the market is global and demand could be in India or any other place because these are difficult-to-make peptides.
- Difelikefalin DMF filing: The first active GDS project; the DMF is expected to be filed later this year (CY24), with the name already in the public domain.
- GLP-1 GDS project: The second active GDS project; the DMF will be filed perhaps in 2026, and the big opportunity is more for the generic side than the CDMO side.
- Label extension: One CMS product received a label extension, noted by an analyst during the call.
Saharsh Davuluri: "I think one GLP-1, CDMO opportunity is very limited because all these companies who are the innovators are securing their own API supply chains by building, making them in-house."
Capex, Capacity & Balance Sheet
- Baseline capex: The company will always spend ₹100-plus crores per year as a baseline, and will be opportunistic if something meets growth plans.
- Land procurement: Land next to Unit 1 was procured for future expansion of products made in those facilities, part of a 5-year plan.
- Plants being built: New facilities are identified with specific products but designed to be multi-product facilities, not necessarily dedicated to a single molecule.
- Working capital improvement: Reduced from 141 days to 122 days; the target is 120 days and management is fairly confident of getting there.
- Operating expense increase: Up approximately 18% as per plan due to manpower costs, professional fees, and manufacturing expenses; this is not a one-off.
- Dividend policy: The company benchmarks against other growing companies and uses guidelines debated in board meetings every year based on profitability to declare dividends; the practice will continue.
- Regulatory inspections: Both Unit 3 and Unit 1 were inspected by the FDA during FY24.
Customer & Competitive Dynamics
- Customer loss is not always bad: Losing a customer at a project level is the nature of the business; molecules in Phase I or II may not progress to the next stage, and that outcome is not necessarily negative.
- Key molecule concentration: Key molecules constituting a substantial portion of commercial revenues are around 4 to 5, and management will keep talking about key additions rather than committing to quarter-on-quarter increases in the commercialized API count.
- Board decisions vs operational trust: The decision to work in India versus keeping a molecule in the West is more of a board decision of the innovator company, and has less to do with whether outsourcing managers have faith in Neuland, partially deflecting the premise that customer perception has fundamentally changed.
Saharsh Davuluri: "The decision of working in India versus keeping a molecule in the West is more of a, I've seen that it's more of a board decision of the innovator company. It's got less to do with whether the outsourcing managers or the CMC groups have faith in Neuland or not."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth moderation | Modest growth in FY25, far better growth in FY26 and FY27 based on current pipeline projections | FY25 / FY26-27 |
| Medium-term growth target | 20% kind of growth over a 4-5 year period, not linear year-on-year | 4-5 year horizon |
| Margin normalization | Normalization to some extent due to investments and input cost increases; business mix expected to remain steady and gradually improve | FY25 |
| Working capital | Target 120 days, fairly confident of achieving | Not specified |
| Baseline capex | ₹100-plus crores per year, opportunistic for growth capex | Ongoing |
| New project inflow increase | Total number of projects should increase in the next 12 months | Next 12 months |
| Difelikefalin DMF filing | First active GDS project, DMF expected to be filed later this year | CY24 |
| GLP-1 GDS DMF filing | Second active GDS project, DMF filing perhaps in 2026 | 2026 |
Key Metrics
| Metric | Q4 FY24 |
|---|---|
| Total income (FY24) | ₹1,571.1 cr, +30.8% YoY |
| Profit after tax | ₹67.6 cr, vs ₹84.5 cr in Q4 FY23 |
| EPS | ₹52.7 per share |
| EBITDA margin (FY24) | 30%, up from 23% in FY23 and 15% in FY22 |
| Gross margin | Compared to 59.8% in Q3 FY24 |
| CMS revenue share (FY24) | Close to 50% of total revenues |
| Operating expenses growth | ~18% as per plan, rest variable; total increase ~21% YoY and ~23% QoQ |
| Net debt | Negative ₹32.6 cr |
| Working capital cycle | 122 days, improved from 141 days at end of March 2023 |
| Capex (FY24) | ₹143.7 cr invested |
| Capex guidance baseline | ₹100-plus cr per year |
| Peak cash flow (FY24) | ₹116.4 cr |
| Debt reduction (FY24) | ₹39.4 cr |
| Total active projects | 88 in FY24, vs 76 in FY20 |
| Commercial CMS projects | 18 (8+10), none involve biologics |